跳至主要内容
临床试验/EUCTR2021-000265-33-NL
EUCTR2021-000265-33-NL进行中(未招募)1 期

Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations - Luxturna follow-up

The Rotterdam Eye Hospital0 个研究点目标入组 20 人开始时间: 2021年1月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Informed consent.
  • - Clinical diagnosis of inherited retinal disease with confirmed bi-allelic RPE65 mutations.
  • - Clinical evidence of viable retinal tissue (RPE cells, photoreceptors, and downstream ganglion cells) as target. Patients have to have more than one characteristic:
  • 1. total retinal thickness > 100 µm in the posterior pole (OCT).
  • 2. area without atrophy of at least three disc diameters (funduscopy).
  • 3. residual island in the central visual field (within 30º of central fixation; Goldmann).
  • - Recordable full-field stimulus test.
  • - Scheduled to receive treatment with Luxturna®.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 10
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - None specified.

研究者

发起方
The Rotterdam Eye Hospital

相似试验